Interim analyses in clinical trials: Why do we plan them?

Journal of Clinical Oncology

Volumn 18, Issue 24, 2000, Pages 4007-4008

  Fossa S D ^a   Skovlund, E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; EDITORIAL; ETHICS; EXPERIMENTATION; HEALTH CARE QUALITY; HUMAN; ONCOLOGY; PATIENT CARE; PRIORITY JOURNAL; STUDY;

EID: 0034671252     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.24.4007     Document Type: Editorial

References (7)

1. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Randomized phase II trial assessing estramustine and vinblastine combination chemotherpy vs estramustine alone in patients with hormone escaped progressive metastatic prostate cancer
4. Interferon-alfa 2A (IFN) with or without 13-cis-retinoid acid (RA) in metastatic renal cell carcinoma (MRCC): Toxicity analysis of an EORTC randomised phase II study
5. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin- 2 and interferon alfa with or without fluorouracil
6. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial - Groupe Francais d'Immunotherapie
7. Randomized phase II clinical trials